Published in Nephrol Dial Transplant on February 01, 2003
Naturally occurring higher hemoglobin concentration does not increase mortality among hemodialysis patients. J Am Soc Nephrol (2010) 2.22
Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am J Kidney Dis (2012) 1.69
Iron sucrose augments homocysteine-induced endothelial dysfunction in normal subjects. Kidney Int (2006) 1.50
Erythropoietin therapy, hemoglobin targets, and quality of life in healthy hemodialysis patients: a randomized trial. Clin J Am Soc Nephrol (2009) 1.01
Chapter 3: Use of ESAs and other agents to treat anemia in CKD. Kidney Int Suppl (2011) (2012) 1.00
Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. Haematologica (2006) 0.99
Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomised controlled trial. BMC Clin Pharmacol (2009) 0.94
Safety issues with intravenous iron products in the management of anemia in chronic kidney disease. Clin Med Res (2008) 0.87
Erythropoietin: physiology and molecular mechanisms. Heart Fail Rev (2008) 0.84
Hemoglobin targets for chronic kidney disease patients with anemia: a systematic review and meta-analysis. PLoS One (2012) 0.81
Use of agents stimulating erythropoiesis in digestive diseases. World J Gastroenterol (2009) 0.79
Influence of safety warnings on ESA prescribing among dialysis patients using an interrupted time series. BMC Nephrol (2013) 0.78
Recombinant human epoetin beta in the treatment of renal anemia. Ther Clin Risk Manag (2007) 0.78
Chronic kidney disease, heart failure and anemia. Can J Cardiol (2008) 0.78
Association Between Vascular Access Dysfunction and Subsequent Major Adverse Cardiovascular Events in Patients on Hemodialysis: A Population-Based Nested Case-Control Study. Medicine (Baltimore) (2015) 0.77
Role of alpha-lipoic acid in the management of anemia in patients with chronic renal failure undergoing hemodialysis. Int J Nephrol Renovasc Dis (2013) 0.77
The impact of hyporesponsiveness to erythropoietin-stimulating agents on time-dependent mortality risk among CKD stage 5D patients: a single-center cohort study. Clin Exp Nephrol (2012) 0.77
Association of higher erythropoiesis stimulating agent dose and mortality in children on dialysis. Pediatr Nephrol (2014) 0.77
Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study. BMC Nephrol (2005) 0.75
Individualizing anaemia therapy. NDT Plus (2010) 0.75
Renal anemia control in Lithuania: influence of local conditions and local guidelines. ScientificWorldJournal (2013) 0.75
Correlation between CRP and early failure of arteriovenous fistula (AVF). Med J Islam Repub Iran (2015) 0.75
Iron inhibits respiratory burst of peritoneal phagocytes in vitro. ISRN Urol (2011) 0.75
De novo weekly and biweekly darbepoetin alfa dosing in pediatric patients with chronic kidney disease. Pediatr Nephrol (2017) 0.75
Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA (2009) 5.52
On the relative safety of parenteral iron formulations. Nephrol Dial Transplant (2004) 2.26
Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant (2005) 2.01
Baroreflex effectiveness index and baroreflex sensitivity predict all-cause mortality and sudden death in hypertensive patients with chronic renal failure. J Hypertens (2007) 1.71
Declining Estimated Glomerular Filtration Rate and Its Association with Mortality and Comorbidity Over 10 Years in Elderly Women. Nephron (2015) 1.51
Biocompatibility and tolerability of a purely bicarbonate-buffered peritoneal dialysis solution. Perit Dial Int (2009) 1.40
Regulation of fibroblast growth factor-23 in chronic kidney disease. Nephrol Dial Transplant (2007) 1.12
Rapid elimination by glomerular filtration of free prostate specific antigen and human kallikrein 2 after renal transplantation. J Urol (2004) 1.06
Increase in percent free prostate-specific antigen in men with chronic kidney disease. Nephrol Dial Transplant (2008) 1.00
Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography. Br J Haematol (2003) 0.99
Preoperative tumor localization by means of venous sampling for fibroblast growth factor-23 in a patient with tumor-induced osteomalacia. Endocr Pract (2008) 0.97
Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment. Nephrol Dial Transplant (2003) 0.93
Fibroblast growth factor-23 and mineral metabolism after unilateral nephrectomy. Nephrol Dial Transplant (2010) 0.93
A new safety device for hemodialysis. Hemodial Int (2008) 0.92
Neutrophil-derived proteinase 3 induces kallikrein-independent release of a novel vasoactive kinin. J Immunol (2009) 0.91
Expression of protein C inhibitor (PCI) in benign and malignant prostatic tissues. Prostate (2003) 0.90
Different elimination patterns of beta-trace protein, beta2-microglobulin and cystatin C in haemodialysis, haemodiafiltration and haemofiltration. Scand J Clin Lab Invest (2008) 0.89
Fibroblast growth factor 23, mineral metabolism and mortality among elderly men (Swedish MrOs). BMC Nephrol (2013) 0.89
Replacement of acetate with citrate in dialysis fluid: a randomized clinical trial of short term safety and fluid biocompatibility. BMC Nephrol (2013) 0.88
Reduced baroreflex effectiveness index in hypertensive patients with chronic renal failure. Am J Hypertens (2005) 0.86
Heart rate variability is decreased in chronic kidney disease but may improve with hemoglobin normalization. J Nephrol (2008) 0.85
Cystatin C as a predictor of all-cause mortality and myocardial infarction in patients with non-ST-elevation acute coronary syndrome. Clin Biochem (2012) 0.84
Increased Levels of Copeptin, a Surrogate Marker of Arginine Vasopressin, Are Associated with an Increased Risk of Chronic Kidney Disease in a General Population. Am J Nephrol (2016) 0.84
Reduction in glomerular pore size is not restricted to pregnant women. Evidence for a new syndrome: 'Shrunken pore syndrome'. Scand J Clin Lab Invest (2015) 0.81
Assessment of intra-individual variation in prostate-specific antigen levels in a biennial randomized prostate cancer screening program in Sweden. Prostate (2005) 0.80
Making sense: a scientific approach to intravenous iron therapy. J Am Soc Nephrol (2004) 0.79
End-stage renal disease: endocrine aspects of treatment. Growth Horm IGF Res (2003) 0.78
Personal dialysis capacity (PDC(TM)) test: a multicentre clinical study. Nephrol Dial Transplant (2003) 0.78
Elevated temporal QT variability index in patients with chronic renal failure. Clin Sci (Lond) (2004) 0.78
[Time for new measurements in kidney disease diagnosis and follow-up]. Lakartidningen (2013) 0.78
Impaired kidney graft survival is associated with the TNF-alpha genotype. Transplantation (2004) 0.77
Toxic epidermal necrolysis and hemolytic uremic syndrome after allogeneic stem-cell transplantation. Pediatr Transplant (2007) 0.77
Evaluation of a new immunoassay for cystatin C, based on a double monoclonal principle, in men with normal and impaired renal function. Nephrol Dial Transplant (2011) 0.77
Hemorheological and hemodynamic changes in predialysis patients after normalization of hemoglobin with epoetin-alpha. Scand J Urol Nephrol (2005) 0.76
Male sex and vascular risk factors affect cystatin C-derived renal function in older people without diabetes or overt vascular disease. Age Ageing (2013) 0.75
Pharmacokinetics and utilization of iron sucrose. Am J Kidney Dis (2003) 0.75
Editorial comment. Association between glomerular filtration rate, free, total, and percent free prostate-specific antigen. Urology (2010) 0.75
Combining Cystatin C and Creatinine Yields a Reliable Glomerular Filtration Rate Estimation in Older Adults in Contrast to β-Trace Protein and β2-Microglobulin. Nephron (2017) 0.75
[Glomerular filtration--the best measure of renal function]. Lakartidningen (2002) 0.75
Achievement of recommended treatment targets for bone and mineral metabolism in haemodialysis patients using paricalcitol: an observational study. Scand J Urol Nephrol (2011) 0.75
Reduced hemodialysis adequacy after hemoglobin normalization with epoetin. J Nephrol (2005) 0.75
[Regional guidelines for preventative nephrology have been well received]. Lakartidningen (2013) 0.75
[Osteomalacia due to phosphate deficiency caused by a tumor. Focus on FGF23 in physiology and clinic]. Lakartidningen (2012) 0.75
A study on the outcome of percutaneous transluminal renal angioplasty in patients with renal failure. Nephron Clin Pract (2006) 0.75
Renal function and its association with blood pressure in Middle Eastern immigrants and native Swedes. J Hypertens (2017) 0.75
Lipids, blood pressure and bone metabolism after growth hormone therapy in elderly hemodialysis patients. J Nephrol (2003) 0.75
Erythropoietin impairs endothelial vasodilatory function in patients with renal anemia and in healthy subjects. Nephron Clin Pract (2005) 0.75